RAD51C and breast cancer: Germline RAD51C pathologic variants have been linked with an increased risk of tubo-ovarian carcinoma (RAD51C mutant RR 7.55, 95% CI = 5.60–10.19) and breast cancer (RAD51C mutant RR 1.99, 95% CI = 1.39–2.85) [100].